FL Tampa의 골수형성이상증후군 임상 시험
골수형성이상증후군 관련 연구 19개가 Tampa 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
피험자 모집 중2상
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
피험자 모집 중1상
- Moffitt Cancer Center, Tampa
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
피험자 모집 중1/2상
- Moffitt Cancer Center, Tampa
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
피험자 모집 중3상
- Moffitt Cancer Center, Tampa
A Study of BGB-11417 in Participants With Myeloid Malignancies
피험자 모집 중1/2상
- Tampa General Hospital, Tampa
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
피험자 모집 중1상
- Moffitt Cancer Center, Tampa
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
피험자 모집 중1/2상
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
피험자 모집 중3상
- Moffitt Cancer Center, Tampa
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
피험자 모집 중2상
- H. Lee Moffitt Cancer Center and Research Center, Tampa
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
피험자 모집 중1상
- H Lee Moffitt Cancer Center & Research Institute, Tampa
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
피험자 모집 중2상
- Moffitt Cancer Center, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- Moffitt Cancer Center, Tampa
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
피험자 모집 중2상
- Moffitt Cancer Center, Tampa
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
피험자 모집 중1상
- Moffitt Cancer Center, Tampa
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
피험자 모집 중1상
- Moffitt Cancer Center, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Tampa
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
피험자 모집 중1상
- Moffitt Cancer Center, Tampa
Study of REM-422 in Patients With AML or Higher Risk MDS
피험자 모집 중1상
- Moffitt Cancer Center, Tampa
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
피험자 모집 중1/2상
- H. Lee Moffitt Cancer Center & Research Institute, Tampa
다른 도시의 골수형성이상증후군 시험
- Houston, TX연구 43개
- Baldwin Park, CA연구 26개
- New York City, NY연구 21개
- Seattle, WA연구 21개
- Washington, DC연구 20개
- Boston, MA연구 19개
- Miami, FL연구 17개
- Durham, NC연구 14개
- Columbus, OH연구 14개
- St. Louis, MO연구 13개
- Atlanta, GA연구 13개
- Chicago, IL연구 13개
Tampa의 다른 연구
- 비소세포폐암연구 51개
- 유방암연구 43개
- 암 (전체)연구 39개
- 대장직장암연구 34개
- 급성 골수성 백혈병연구 29개
- 전이성 암연구 29개
- 폐암연구 29개
- 췌장암연구 26개
- 난소암연구 21개
- 흑색종연구 19개
- 전립선암연구 18개
- 심부전연구 18개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.